Preferred Label : Anti-CD24/Anti-4-1BB Bispecific Monoclonal Antibody IBD0333;
NCIt synonyms : 4-1BB/CD24 Bispecific Antibody IBD0333; Anti-CD24 x 4-1BB Bispecific Monoclonal Antibody IBD0333; Anti-CD24/4-1BB Bispecific Monoclonal Antibody IBD0333; Anti-CD24/Anti-CD137 Bispecific Antibody IBD0333; Anti-4-1BB/Anti-CD24 Bispecific Monoclonal Antibody IBD0333;
NCIt definition : A bispecific monoclonal antibody targeting the cell surface antigen cluster of differentiation
24 (CD24) and the costimulatory receptor 4-1BB (CD137; tumor necrosis factor receptor
superfamily member 9; TNFRSF9), with potential immunostimulating and antineoplastic
activities. Upon administration, anti-CD24/anti-4-1BB bispecific monoclonal antibody
IBD0333 simultaneously targets and binds to CD24 expressed on the surface of tumor
cells and 4-1BB expressed on a variety of leukocyte subsets including activated T-lymphocytes.
This crosslinks CD24-expressing tumor cells and 4-1BB-expressing T-cells, and activates
4-1BB signaling locally in the tumor microenvironment (TME). This results in cytotoxic
T-cell co-stimulation, enhances T-lymphocyte-mediated anti-tumor activity and leads
to cytotoxic T-cell-mediated lysis of CD24-expressing tumor cells. CD24, a glycophosphatidylinositol
(GPI)-anchored, highly glycosylated cell adhesion protein, is overexpressed on the
surface of a variety of cancer cells. Expression of CD24, and its interaction with
Siglec-10, protects cancer cells from phagocytosis, thereby allowing cancer cells
to proliferate. Its expression is correlated with poor prognosis. 4-1BB, a surface
glycoprotein of the tumor necrosis factor receptor superfamily, is an inducible costimulatory
receptor that plays a key role in T-cell proliferation, survival and cytolytic activity.;
Molecule name : IBD 0333; IBD-0333;
Origin ID : C209755;
chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
